

List of Figures

Figure Name	Page No.
Figure 1: Multistep of Cancer Process	8
Figure 2: Locus chromosomes 14 and 18 containing the BCL-2 Some basic features of BCL-2	9
Figure 3: Apoptosis increasing from normal cells (top) to apoptotic ones (bottom)	12
Figure 4: The role of mitochondria on process of apoptosis	14
Figure 5: Bioinformatics relation with other sciences	15
Figure 6: The docking of drug molecule and (red) to a protein receptor (blue)	17
Figure 7: Schematic diagram illustrating the docking of a small molecule (brown) to a protein receptor (green) to produce a complex	18
Figure 8: Small molecule docked to a protein.	18
Figure 9: Clustal multiple sequence alignment	30
Figure 10: Structure of the BCL2L10 protein	31
Figure 11: Graphical representation for verify 3D	31
Figure 12: Ramachandran Plot using RAMPAGE server	32
Figure 13: Compare the structure of Bcl2L10(represented in Red color) with 2KUA (represented with Blue color)	33
Figure 14: Active site of protein Bcl2L10	34
Figure 15: Docking of Bcl2L10 with drug (No 1) on level 35.52	60
Figure 16: Docking of Bcl2L10 with drug (No 22) on level 36.31	60

Figure 17: Docking of Bcl2L10 with drug (No 23) on level 36.31	61
Figure 18: Docking of Bcl2L10 with drug (No 26) on level 37.38	61
Figure 19: Docking of Bcl2L10 with drug (No 10) on level 38.50	62
Figure 20: Docking of Bcl2L10 with drug (No 11) on level 40.11	62
Figure 21: Docking of Bcl2L10 with drug (No 25) on level 37.17	63
Figure 22: Docking of Bcl2L10 with drug (No 97) on level 41.17	63
Figure 23: Docking of Bcl2L10 with drug (No 30) on level 37.88	64
Figure 24: Docking of Bcl2L10 with drug (No 55) on level 38.77	64
Figure 25: Docking of Bcl2L10 with drug (No 63) on level 40.20	65
Figure 26: Docking of Bcl2L10 with drug (No 64) on level 40.54	65
Figure 27: Docking of Bcl2L10 with drug (No 78) on level 40.16	66
Figure 28: Docking of Bcl2L10 with drug (No 96) on level 39.22	66
Figure 29: Docking of Bcl2L10 with drug (No 42) on level 36.39	67
Figure 30: Docking of Bcl2L10 with drug (No 49) on level 36.62	67
Figure 31: Docking of Bcl2L10 with drug (No 50) on level 37.22	68
Figure 32: Docking of Bcl2L10 with drug (No 56) on level 37.42	68
Figure 33: Docking of Bcl2L10 with drug (No 57) on level 39.50	69
Figure 34: Docking of Bcl2L10 with drug (No 58) on level 36.81	69
Figure 35: Docking of Bcl2L10 with drug (No 59) on level 36.12	70
Figure 36: Docking of Bcl2L10 with drug (No 84) on level 35.60	70

Figure 37: Docking of Bcl2L10 with drug (No 94) on level 38.77	71
Figure 38: Docking of Bcl2L10 with drug (No 95) on level 37.04	71
Figure 39: Docking of Bcl2L10 with drug (No 54) on level 36.82	72

List of Tables

Table Name	Page No.
Table 1: Predicted Distribution of U.S. Cancer Deaths in 2008	5
Table 2: Individual for each ligand docked with protein in GOLD	57

Abstract

Cancer known medically as a malignant neoplasm, is a large group of different diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade nearby parts of the body. Homology modeling and flexible docking of Bcl2L10 has been studied in *silico* approach. Blast result was found to have similarity with Bcl2L10 of 48% identity with 2KUA. With the aid of Molecular dynamics and Molecular simulations studies it was identified that the generated structure was reliable. Active site of Bcl2L10 was identified by CASTP. Large potential drugs were designed for identifying molecules that can likely bind to protein target of interest. This structure was used to identify better inhibitor using docking studies. The drug derivatives were docked to the Bcl2L10 structure into the active site. The different drug derivatives designed were used for docking with the generated structure, among the 100 derivatives designed, fifth derivative showed highest docking result. The drug derivatives were docked to the protein by hydrogen bonding interactions and these interactions play an important role in the binding studies. Our investigations may be helpful for further studies.

Key words: BCL2L10, Cancer, Drug Designing, Modelling, Molecular dynamics.

Aim and Objectives

The main objective of this study is to help in treating cancer disease cause by Bcl2L10 by exploiting drug that docking with Bcl2L10. This study investigated in *silico* approach for identification inhibitor design with protein caused cancer. The project work is carried out on the following objectives:

- Prediction 3 D structure of protein
- Designing inhibitor drugs that may bind with protein
- Active-site identification
- screening the inhibitor drugs that docking with protein